Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Bonate

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumorsAlain C Mita, Lisa A Hammond, Peter L Bonate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumorsCasey Cunningham, Leonard J Appleman, Miora Kirvan-Visovatti, et al.
Blood|May 5, 2010
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1Elena Lukina, Nora Watman, Elsa Avila Arreguin, et al.
Clinical Pharmacokinetics|April 12, 2024
Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid TumorsMei Tang, Amit Garg, Peter L Bonate, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 13, 2023
Training the next generation of pharmacometric modelers: a multisector perspectivePeter L Bonate, Jeffrey S Barrett, Sihem Ait-Oudhia, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 5, 2023
Correction to: Training the next generation of pharmacometric modelers: a multisector perspectivePeter L Bonate, Jeffrey S Barrett, Sihem Ait-Oudhia, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumorsAlain C Mita, Lisa A Hammond, Peter L Bonate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumorsCasey Cunningham, Leonard J Appleman, Miora Kirvan-Visovatti, et al.
Blood|May 5, 2010
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1Elena Lukina, Nora Watman, Elsa Avila Arreguin, et al.
Clinical Pharmacokinetics|April 12, 2024
Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid TumorsMei Tang, Amit Garg, Peter L Bonate, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 13, 2023
Training the next generation of pharmacometric modelers: a multisector perspectivePeter L Bonate, Jeffrey S Barrett, Sihem Ait-Oudhia, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 5, 2023
Correction to: Training the next generation of pharmacometric modelers: a multisector perspectivePeter L Bonate, Jeffrey S Barrett, Sihem Ait-Oudhia, et al.
Pageof 7